Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.35 as of 2026-09-25T00:15:59.198Z.
Consensus retrieved: 2026-09-13T23:39:06.640Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-25T00:15:59.198Z.
Quote observation: 2026-09-24T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d36a9ef3dd00a3b0176393925906ed0ad09061a29621a98fe511a29c7f47a262
Forward PE Ratio (18.35) = Dated Quote Price ($221.89) / Consensus Forward EPS ($12.09)
FORWARD PE RATIO
18.35
SECTOR MEDIAN · HEALTHCARE
18.75
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-2.13%
vs the sector median at left
ResMed Inc.
Market Cap
$32.19B
Forward PE Ratio
18.35
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ResMed Inc. (RMD) | $32.19B | 18.35 |
| Alcon Inc. (ALC)vs › | $31.49B | 18.55 |
| DexCom, Inc. (DXCM)vs › | $33.01B | 32.79 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $33.40B | 37.40 |
| Biogen Inc. (BIIB)vs › | $33.45B | 18.23 |
| Mettler-Toledo International Inc. (MTD)vs › | $30.70B | 32.10 |
| Centene Corp. (CNC)vs › | $30.58B | 12.89 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.98B | 13.48 |
| Zoetis Inc. (ZTS)vs › | $29.48B | 11.24 |
| Medline Inc. (MDLN)vs › | $29.31B | 23.22 |
Trailing P/E
21.3
reported TTM EPS
Forward P/E
18.4
consensus EPS · fiscal year ending 2027-06-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $12.09 implies +16.2% EPS growth vs the reported trailing $10.40.
At the dated quote price of $221.89, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $12.09 | $11.81 – $12.32 | 14 | 18.3x |
| 2028-06-30 | $13.30 | $13.13 – $13.69 | 14 | 16.7x |
| 2029-06-30 | $14.51 | $12.88 – $15.21 | 7 | 15.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
